179 related articles for article (PubMed ID: 15060172)
1. How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM; Siu WY; Lau A; Poon RY
Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
[TBL] [Abstract][Full Text] [Related]
2. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
3. MDM2 suppresses p73 function without promoting p73 degradation.
Zeng X; Chen L; Jost CA; Maya R; Keller D; Wang X; Kaelin WG; Oren M; Chen J; Lu H
Mol Cell Biol; 1999 May; 19(5):3257-66. PubMed ID: 10207051
[TBL] [Abstract][Full Text] [Related]
4. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.
Nozaki M; Tada M; Kashiwazaki H; Hamou MF; Diserens AC; Shinohe Y; Sawamura Y; Iwasaki Y; de Tribolet N; Hegi ME
Brain Pathol; 2001 Jul; 11(3):296-305. PubMed ID: 11414472
[TBL] [Abstract][Full Text] [Related]
5. SSRP1 functions as a co-activator of the transcriptional activator p63.
Zeng SX; Dai MS; Keller DM; Lu H
EMBO J; 2002 Oct; 21(20):5487-97. PubMed ID: 12374749
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.
Wiech M; Olszewski MB; Tracz-Gaszewska Z; Wawrzynow B; Zylicz M; Zylicz A
PLoS One; 2012; 7(12):e51426. PubMed ID: 23251530
[TBL] [Abstract][Full Text] [Related]
7. p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101.
Ruland J; Sirard C; Elia A; MacPherson D; Wakeham A; Li L; de la Pompa JL; Cohen SN; Mak TW
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1859-64. PubMed ID: 11172041
[TBL] [Abstract][Full Text] [Related]
8. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes.
Menendez D; Inga A; Resnick MA
Mol Cell Biol; 2006 Mar; 26(6):2297-308. PubMed ID: 16508005
[TBL] [Abstract][Full Text] [Related]
9. Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA.
Lepre MG; Omar SI; Grasso G; Morbiducci U; Deriu MA; Tuszynski JA
Molecules; 2017 Aug; 22(8):. PubMed ID: 28813011
[TBL] [Abstract][Full Text] [Related]
10. p53 Oligomerization is essential for its C-terminal lysine acetylation.
Itahana Y; Ke H; Zhang Y
J Biol Chem; 2009 Feb; 284(8):5158-64. PubMed ID: 19106109
[TBL] [Abstract][Full Text] [Related]
11. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
12. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.
Frazier MW; He X; Wang J; Gu Z; Cleveland JL; Zambetti GP
Mol Cell Biol; 1998 Jul; 18(7):3735-43. PubMed ID: 9632756
[TBL] [Abstract][Full Text] [Related]
13. Effects of stability on the biological function of p53.
Khoo KH; Mayer S; Fersht AR
J Biol Chem; 2009 Nov; 284(45):30974-80. PubMed ID: 19700401
[TBL] [Abstract][Full Text] [Related]
14. Discovery of compounds that reactivate p53 mutants in vitro and in vivo.
Durairaj G; Demir Ö; Lim B; Baronio R; Tifrea D; Hall LV; DeForest JC; Lauinger L; Jebril Fallatah MM; Yu C; Bae H; Lin DW; Kim JK; Salehi F; Jang C; Qiao F; Lathrop RH; Huang L; Edwards R; Rychnovsky S; Amaro RE; Kaiser P
Cell Chem Biol; 2022 Sep; 29(9):1381-1395.e13. PubMed ID: 35948006
[TBL] [Abstract][Full Text] [Related]
15. Predicting transcriptional activity of multiple site p53 mutants based on hybrid properties.
Huang T; Niu S; Xu Z; Huang Y; Kong X; Cai YD; Chou KC
PLoS One; 2011; 6(8):e22940. PubMed ID: 21857971
[TBL] [Abstract][Full Text] [Related]
16. Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand.
Gordo S; Martos V; Santos E; Menéndez M; Bo C; Giralt E; de Mendoza J
Proc Natl Acad Sci U S A; 2008 Oct; 105(43):16426-31. PubMed ID: 18940924
[TBL] [Abstract][Full Text] [Related]
17. p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form.
Sengupta S; Singh N; Paul A; Datta D; Chatterjee D; Mukherjee S; Gadhe L; Devi J; Mahesh Y; Jolly MK; Maji SK
J Cell Sci; 2023 Sep; 136(17):. PubMed ID: 37622400
[TBL] [Abstract][Full Text] [Related]
18. Microchip-Based Structure Determination of Disease-Relevant p53.
Solares MJ; Jonaid GM; Luqiu WY; Liang Y; Evans MC; Dearnaley WJ; Sheng Z; Kelly DF
Anal Chem; 2020 Dec; 92(23):15558-15564. PubMed ID: 33124814
[TBL] [Abstract][Full Text] [Related]
19. Prediction of P53 mutants (multiple sites) transcriptional activity based on structural (2D&3D) properties.
Ramani RG; Jacob SG
PLoS One; 2013; 8(2):e55401. PubMed ID: 23468845
[TBL] [Abstract][Full Text] [Related]
20. p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain "License to Kill".
Stieg D; Casey K; Murphy ME
Cancer Discov; 2023 May; 13(5):1046-1048. PubMed ID: 37139723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
